R-RID - Rifaximin to Reduce Infection in Decompensated Cirrhosis

• Research type

  Research Study

• Full title

  A multi-centre, double-blind, randomised, controlled clinical trial of Rifaximin to reduce infection in patients admitted to hospital with decompensated cirrhosis

• IRAS ID

  201854

• Contact name

  Mark Thursz

• Contact email

  m.thursz@imperial.ac.uk

• Sponsor organisation

  Imperial College London

• Eudract number

  2016-002628-96

• ISRCTN Number

  ISRCTN10994757

• Duration of Study in the UK

  2 years, 11 months, 31 days

• Research summary

  A multi-centre, Investigator-led, Imperial College sponsored, double-blind, randomised, controlled clinical trial of Rifaximin to reduce infection in patients admitted to hospital with decompensated cirrhosis.

  Patients will be randomised at a ratio of 1:1 to either receive Rifaximin or placebo and research samples (blood, urine & stool) will be collected for laboratory analysis to perform the following:

  Monocyte Phenotyping (FACS analysis;
  ELISA (sMER);
  Bacterial DNA Quantification;
  Metabolic Profiling

• REC name

  South West - Central Bristol Research Ethics Committee

• REC reference

  16/SW/0232

• Date of REC Opinion

  20 Sep 2016

• REC opinion

  Further Information Favourable Opinion